At BeiGene, we are committed to discovering and developing innovative products that will bring meaningful value to people with cancer around the world. We conduct clinical trials to study the safety and effectiveness of our investigational medicines and believe that participating in clinical trials, whenever possible, is an important way for patients to obtain access to investigational medicines while helping deepen the pool of knowledge on these investigational therapies.
Types of Access
Clinical trials are human research studies designed to evaluate if an investigational medicine is safe and effective for patients. People who choose to participate in clinical trials play a vital role in developing new medicines, which may support approval by regulatory health authorities and make these medicines more broadly available to patients who may need them. To learn more about BeiGene’s ongoing clinical trials, including your potential eligibility to participate, consult with your doctor or visit our clinical trials page.
In some cases, patients with a serious or life-threatening disease or medical condition may not be able to access one of our investigational medicines through a clinical trial and may not have other treatment options available. In very specific circumstances, these patients may be able to receive investigational medicines outside a controlled clinical trial through Compassionate Use Programs (also sometimes referred to as “Pre-Approval Access,” “Expanded Access,” “Early Access,” “Named Patient Programs,” or “Special Access”). In all cases, providing an investigational medicine through these programs must be done in compliance with the regulations of the appropriate local health authority. Requests are reviewed based on scientific and clinical evidence and a number of important medical criteria including that:
- The disease is serious or life threatening;
- All other available alternative therapies have been exhausted, but the patient may still benefit from further treatment with a BeiGene investigational product;
- A clinical study is not available, either because patients are ineligible or because they have no access to the trial;
- The efficacy and safety data available at the time are of sufficient strength to determine whether the benefit to patient would likely outweigh the potential risks; and
- Access is compliant with local rules and laws.